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ciety for Vascular Surgery (SVS) wound, ischemia, and foot
infection (WIfI) classiﬁcation system correlates with impor-
tant clinical outcomes for limb salvage and wound healing.
Methods: We analyzed 201 consecutive patients with
threatened limbs treated from 2010 to 2011 in an aca-
demic center. We stratiﬁed patients into clinical stages 1
to 4 based on the SVS WIfI classiﬁcation. We compared
the SVS objective performance goals of major amputation,
1-year amputation-free survival rate (AFS), and wound
healing time (WHT) according to WIfI clinical stages.
Results: Patients were a mean age of 59 years, 79%
were men, and 86% had diabetes. Forty-two patients
(21%) required major amputation, and 159 (78%) had
limb salvage. The amputation group had a signiﬁcantly
higher prevalence of advanced stage 4 patients (P <
.001), whereas the limb salvage group presented predomi-
nantly as stages 1 to 3. Patients in clinical stages 3 and 4
had a signiﬁcantly higher incidence of amputation (P <
.001), decreased AFS (P < .001), and delayed WHT
(P < .001) compared with those in stages 1 and 2. Among
patients presenting with stage 3, primarily as a result of
wound and ischemia, revascularization resulted in acceler-
ated WHT (P ¼ .008).
Conclusions: These data support the underlying
concept of the SVS WIfI classiﬁcation. As the clinical stage
progresses, the risk of major amputation increases, 1-year
AFS declines, and time to wound healing is prolonged.
We further demonstrated beneﬁt of revascularization to
improve WHT in selected patients, especially those in stage
3. Future efforts are warranted to incorporate the SVS
WIfI classiﬁcation into clinical decision-making algorithms
in conjunction with a comorbidity index and anatomic
classiﬁcation.
Table.
Amputation, 1-year AFS, Mean WHT (95% CI),
Stage No. % (n) % (n) (days)1 39 0 (0) 100 (39) 94 (69-119)
2 50 0 (0) 100 (50) 115 (92-138)
3 53 8 (4) 92 (49) 162 (105-220)
4 59 64 (38) 63 (38) 263 (167-360)AFS, Amputation-free survival; CI, conﬁdence interval; WHT, wound
healing time.
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Healthcare Delivery Redesign for EVAR Leads to
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Courtney J. Warner, Richard J. Powell, Alexander J.
Horvath, Jesse A. Columbo, Teri R. Walsh, Philip P.
Goodney, Daniel B. Walsh, David H. Stone. Dartmouth-
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Objectives: Endovascular aneurysm repair (EVAR) is
now a mainstay of therapy for abdominal aortic aneurysm,
although it remains associated with signiﬁcant expense. We
performed a comprehensive analysis of EVAR delivery at an
academic medical center to identify targets for qualityimprovement and cost reduction in light of impending
health care reform.
Methods: All infrarenal EVARs performed from April
2011 to March 2012 were identiﬁed (n ¼ 127). Proce-
dures were included if they met standard commercial in-
structions for use guidelines, used a single manufacturer,
and were billed to Medicare Diagnosis-Related Group
238 (n ¼ 49). Using DMAIC (deﬁne, measure, analyze,
improve, control) quality improvement methodology, tar-
gets for EVAR quality improvement were identiﬁed, and
high-yield changes were implemented. Procedure technical
costs were calculated before and after process redesign.
Results: Perioperative services and clinic visits were
identiﬁed as targets for quality improvement efforts and
cost reduction. Mean technical costs before the interven-
tion were $31,672, with endograft implants accounting
for 52%. Pricing redesign in collaboration with hospital
purchasing reduced mean EVAR technical costs to
$28,607, a 10% reduction in overall cost, with endograft
implants now accounting for 46%. Perioperative implemen-
tation of instrument tray redesign reduced instrument use
by 32% (184 vs 132 instruments), saving $50,000 annually.
Unnecessary clinic visits were reduced by 39% (1.6 vs 1.1
clinic visits per patient) through implementation of a pre-
clinic imaging protocol. There was no difference in mean
length of stay after the intervention (2.85 vs 2.45 days,
P ¼ NS).
Conclusions: Comprehensive EVAR delivery redesign
leads to cost reduction and waste elimination, while preser-
ving quality. Future efforts aimed to achieve more compet-
itive and transparent device pricing will make EVAR more
cost neutral and enhance its ﬁnancial sustainability for
healthcare systems.
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Objectives: To prospectively evaluate the neurologic
status of all patients undergoing carotid revascularization
in a single institution during a 6-year period.
Methods: Between January 2007 and June 2013, all
patients undergoing carotid revascularization underwent in-
dependent neurologic evaluation preprocedure, postproce-
dure, and at 30 days. Symptom status (symptomatic vs
asymptomatic), participation in clinical trials, stroke, death,
andmyocardial infarction (MI)were independently reviewed.
c2 Analysis and the Fisher exact test were performed.
Results: A total of 2301 interventions were per-
formed: 1969 carotid endarterectomies (CEA) 85.6% and
332 carotid angioplasty and stent procedures (CAS)
14.4%. Stroke/death/MI was 5.0%. Of 1814 patients,
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(32%) and in 1233 asymptomatic patients (68%). Stroke/
death/MI was 4.5% (2.8%/0.5%/1.2%) for symptomatic
patients and 4.0% (2.4%/0.4%/1.1%) for asymptomatic pa-
tients. CEA and coronary artery bypass grafting (CABG)
was performed in 155 patients (98.7% asymptomatic),
S/D/MI of 11.1% (3.9%/5.8/%1.3%). Of 332 patients,
CAS was performed in 119 symptomatic patients (36%)
and in 213 asymptomatic patients (64%), with 255 (77%)
treated as part of a Food and Drug Administration-
approved trial. S/D/MI was 9.2% (4.2%/4.2%/0.8%) for
symptomatic patients and 5.2% (3.3%/1.4%/0.4%) for
asymptomatic patients. Symptomatic CAS patients treated
in a clinical trial (n ¼ 64) had two eventsdS/D/MI of
3.1% (3.1%/0%/0%). Symptomatic patients treated outside
a clinical trial (n ¼ 55) had nine eventsdS/D/MI of
16.4% (5.5%/9%/1/1.8%).
Conclusions: (1). The prospectively collected, inde-
pendently veriﬁed S/D/MI rates for all CEA and CAS
performed within a clinical trial were equivalent to the
CREST results. (2) S/D/MI for CAS in symptomatic
patients was signiﬁcantly higher than CEA (9.2% vs
4.5%; P ¼ .034). (3). S/D/MI for CAS in symptomatic
patients within a clinical trial was equivalent to CEA
(3.1% vs 4.5%; P ¼ .759). Symptomatic CAS patients
who did not qualify for a clinical trial had a ﬁve times
increased risk of S/D/MI of 16.4%. (4) S/D/MI for
CAS in asymptomatic patients was equivalent to CEA
(5.2% vs 4.0%; P ¼ .42). (5). CEA/CABG in asymptom-
atic patients is associated with a three-times increased risk
of S/D/MI compared with patients undergoing CEA for
asymptomatic disease.
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Kinematics Effectively Delineate Accomplished Users
of Endovascular Robotics Using a Physical Training
Model
Cassidy Duran1, Sean Estrada2, Marcia O’Malley2, Jean
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Objectives: Endovascular robotics systems, now
approved for clinical use in the United States and Europe,
are seeing rapid growth in interest. Determining who has
sufﬁcient expertise for safe and effective clinical use remains
elusive. Our aim was to analyze performance on a robotic
platform to determine what deﬁnes an expert user.
Methods: Over three sessions, 20 subjects with a
range of endovascular expertise and endovascular robotic
experience (novices <2 hours to moderate-extensive expe-
rience with >20 hours), performed four tasks on a training
model. All participants completed a 2-hour training session
on the robot by a certiﬁed instructor. Electromagnetic
tracking was used to capture and analyze catheter tip mo-
tion. Motion analysis was based on derivations of speed
and position, including spectral arc length and totalnumber of submovements (inversely proportional to proﬁ-
ciency of motion) and duration of submovements (directly
proportional to proﬁciency).
Results: There was no signiﬁcant difference in
completion times between novices and experienced users.
The experienced users had more efﬁcient motion and per-
formed more consistently. Users with >20 hours per-
formed signiﬁcantly better than those new to the system,
independent of standard endovascular experience (Table).
Conclusions: Expertise in performance of traditional
manual endovascular interventions does not translate to
performance on the endovascular robot. Efﬁciency of cath-
eter movement and consistency of performance may help
identify users who are sufﬁciently trained for safe clinical
use of the system. This work will help identify the learning
curve and speciﬁc movements that translate to expert ro-
botic navigation.
Table. Motion metrics for robotic task performance
Competent Noncompetent PSpectral arc length, mean mm 18.18 28.82 <.0001
Submovements
Mean number per sec 0.415 0.642 <.0001
Mean duration, sec 3.27 1.77 <.0001Author Disclosures: J. Bismuth: Hansen Medical,
consulting fees or other remuneration (payment); C.
Duran: Nothing to disclose; S. Estrada: Nothing to
disclose; M. O’Malley: Nothing to disclose.
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Surgical Aneurysmorrhaphy to Preserve Autogenous
Arteriovenous Fistula (aAVF) With Aneurysm-
Related Complications
Trung Vo, Gloria Tumbaga, Paul Aka, Jeffrey Hsu, Jason
Behseresht, Majid Tayyarah. Kaiser Permanente Fontana,
Fontana, Calif
Objectives: Aneurysm related complications can result
in lost of a functioning autogenous arteriovenous ﬁstula
(aAVF). We reviewed our results with aneurysmorrhaphy
to preserve and extend the aAVF use span.
Methods: Over the past 6-year period, we retrospec-
tively reviewed the surgical outcome in patients with an
aAVF who presented with aneurysm-related bleeding,
infection, and/or skin erosion. Of 50 patients who were
identiﬁed, 36 (72%) underwent aneurysmorrhaphy. The
operation involves resecting the redundant aneurysm wall
along with compromised skin and primarily remodeling
the remaining vein to create a conduit 6 to 8mm in diameter.
Results: Thirty-four of 36 (94%) complicated AVFs
were successfully repaired primarily with aneurysmorrha-
phy. Median patient age was 65.5 years (range, 29-88
years). Median AVF age was 61.5 months (range, 12-136
months). Median patient follow-up was 15.5 months
(range, 1-76 months). Seventy-ﬁve percent of patients
had at least 9 months of follow-up, and 25% had at least
28 months. Primary patency was 67% and 57%, assisted pri-
mary patency was 85% and 80%, and secondary patency was
89% and 89% at 1 and 2 years, respectively. Local regional
